Preclinical and clinical evidence of Nurr1 involvement in neurodegenerative diseases such as AD, PD and MS has fueled the development of Nurr1 agonists as potential therapeutics in neurodegeneration2,4,6,7. This evidence concerns the gene NR4A2 and Parkinson disease.